HK35397A - Use of hyaluronic acid and forms to prevent arterial restenosis - Google Patents

Use of hyaluronic acid and forms to prevent arterial restenosis

Info

Publication number
HK35397A
HK35397A HK35397A HK35397A HK35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A
Authority
HK
Hong Kong
Prior art keywords
forms
hyaluronic acid
arterial restenosis
prevent arterial
prevent
Prior art date
Application number
HK35397A
Other languages
English (en)
Inventor
Rudolf Edgar Falk
Samuel Simon Asculai
Eva Anne Turley
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA1993/000388 external-priority patent/WO1994007505A1/fr
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of HK35397A publication Critical patent/HK35397A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK35397A 1992-09-25 1997-03-20 Use of hyaluronic acid and forms to prevent arterial restenosis HK35397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002079205A CA2079205C (fr) 1992-09-25 1992-09-25 Utilisation de l'acide hyaluronique et de formules pour empecher la restenose arterielle
PCT/CA1993/000388 WO1994007505A1 (fr) 1991-07-03 1993-09-22 Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle

Publications (1)

Publication Number Publication Date
HK35397A true HK35397A (en) 1997-03-27

Family

ID=4150463

Family Applications (1)

Application Number Title Priority Date Filing Date
HK35397A HK35397A (en) 1992-09-25 1997-03-20 Use of hyaluronic acid and forms to prevent arterial restenosis

Country Status (26)

Country Link
EP (1) EP0661981B1 (fr)
JP (1) JP3742955B2 (fr)
CN (1) CN1057908C (fr)
AP (1) AP448A (fr)
AT (1) ATE141054T1 (fr)
AU (1) AU670117B2 (fr)
BR (1) BR9307221A (fr)
CA (1) CA2079205C (fr)
CZ (1) CZ288986B6 (fr)
DE (1) DE69303931T2 (fr)
DK (1) DK0661981T3 (fr)
ES (1) ES2091031T3 (fr)
GR (1) GR3021171T3 (fr)
HK (1) HK35397A (fr)
HU (2) HU227067B1 (fr)
IL (1) IL107087A0 (fr)
IN (1) IN181289B (fr)
MD (1) MD960294A (fr)
MX (1) MX9305887A (fr)
NO (1) NO309457B1 (fr)
NZ (1) NZ255978A (fr)
PL (1) PL308201A1 (fr)
SG (1) SG48845A1 (fr)
SK (1) SK36895A3 (fr)
TW (1) TW271401B (fr)
ZA (1) ZA937068B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CN1101405C (zh) * 1997-08-22 2003-02-12 电气化学工业株式会社 透明质酸凝胶的制备方法、用此方法制得的透明质酸及包含这种凝胶的医用材料
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques

Also Published As

Publication number Publication date
NO951122D0 (no) 1995-03-23
CA2079205C (fr) 1998-02-10
JPH08506797A (ja) 1996-07-23
HU227067B1 (en) 2010-06-28
AU670117B2 (en) 1996-07-04
CZ288986B6 (cs) 2001-10-17
ES2091031T3 (es) 1996-10-16
DE69303931D1 (de) 1996-09-12
HUT73637A (en) 1996-08-28
PL308201A1 (en) 1995-07-24
AP448A (en) 1996-01-18
SK36895A3 (en) 1997-03-05
CA2079205A1 (fr) 1994-03-26
TW271401B (fr) 1996-03-01
EP0661981B1 (fr) 1996-08-07
ATE141054T1 (de) 1996-08-15
DE69303931T2 (de) 1997-01-09
AP9300568A0 (en) 1993-10-31
CN1057908C (zh) 2000-11-01
DK0661981T3 (da) 1996-12-23
EP0661981A1 (fr) 1995-07-12
CN1092654A (zh) 1994-09-28
MX9305887A (es) 1994-05-31
JP3742955B2 (ja) 2006-02-08
GR3021171T3 (en) 1996-12-31
IL107087A0 (en) 1993-12-28
NZ255978A (en) 1997-02-24
BR9307221A (pt) 1999-07-27
AU4812693A (en) 1994-04-26
CZ66295A3 (en) 1996-02-14
NO309457B1 (no) 2001-02-05
HU9500857D0 (en) 1995-05-29
NO951122L (no) 1995-03-23
SG48845A1 (en) 1998-05-18
MD960294A (ro) 1997-10-31
HU211698A9 (en) 1995-12-28
IN181289B (fr) 1998-05-02
ZA937068B (en) 1994-04-18

Similar Documents

Publication Publication Date Title
TW270115B (fr)
TW225534B (fr)
HU9403323D0 (en) 4-mercaptioacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
EG20279A (en) New derivatives of 3 arylpyrazoles used as fungicides
AU6422294A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
ZA931489B (en) Use of interleuken-10 to suppress graft-vs-host disease
GB9320785D0 (en) Dibenzylheterocyclic or dibenzylcycloalkyl derivatives as inhibitors of hiv intergrase
HU9500857D0 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
BG99421A (en) Glycogen polysacccharides
EP0446852A3 (en) Use of polyglycolic acid and its derivatives as nucleating agent
MY106615A (en) Stabilized leukocyte-interferons.
IL104132A0 (en) Compositions for the treatment of mammalian diseases
GB9318000D0 (en) Inhibition of vascular restenosis
ITPD920013V0 (it) Struttura di cinturino
HU9601498D0 (en) Use of dimeticone for treating constipation
AU7022496A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
GB2250217B (en) Treatment of gas
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases
ZA916434B (en) The use of formamidine sulfinic acid as an oxygen scavenger
CA2117330A1 (fr) Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie
SI0760668T1 (en) Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
GB9218530D0 (en) Monitor of haemostasis
GB9126079D0 (en) The treatment of inflammatory diseases
GB9200568D0 (en) Preparation of an artefact

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130921